vaccine_dirt_1

The dirty little secret for making better vaccines

U. TEXAS-AUSTIN (US) — A menu of 61 new strains of genetically engineered bacteria may mean better vaccines for diseases like flu, whooping cough, cholera, and HPV.

The strains of E. coli are part of a new class of biological “adjuvants”—substances added to vaccines to boost the human immune response—that are poised to transform vaccine design, researchers say.

“For 70 years the only adjuvants being used were aluminum salts,” says Stephen Trent, associate professor of biology at the University of Texas at Austin. “They worked, but we didn’t fully understand why, and there were limitations. Then four years ago the first biological adjuvant was approved by the Food and Drug Administration. I think what we’re doing is a step forward from that. It’s going to allow us to design vaccines in a much more intentional way.”

Adjuvants were discovered in the early years of commercial vaccine production, when it was noticed that batches of vaccine that were accidentally contaminated often seemed to be more effective than those that were pure.

“They’re called the ‘dirty little secret’ of immunology,” Trent says. “If the vials were dirty, they elicited a better immune response.”

What researchers eventually realized was that they could produce a one-two punch by intentionally adding their own dirt (adjuvant) to the mix. The main ingredient of the vaccine, which was a killed or inactivated version of the bacteria or virus that the vaccine was meant to protect against, did what it was supposed to do. It “taught” the body’s immune system to recognize it and produce antibodies in response to it.

The adjuvant amplifies that response by triggering a more general alarm, which puts more agents of the immune system in circulation in the bloodstream, where they can then learn to recognize the key antigen. The result is an immune system more heavily armed to fight the virus or bacteria when it encounters it in the future.

For about 70 years the adjuvant of choice, in nearly every vaccine worldwide, was an aluminum salt. Then in 2009, the FDA approved a new vaccine for human papillomavirus (HPV). It included a new kind of adjuvant that’s a modified version of an endotoxin molecule.

These molecules, which can be dangerous, appear on the cell surface of a wide range of bacteria. As a result, humans have evolved over millions of years to detect and respond to them quickly. They trigger an immediate red alert.

“In some of its forms an endotoxin can kill you,” Trent says. “But the adjuvant, which is called MPL, is a very small, carefully modified piece of it, so it’s able to trigger the immune response without overdoing it.”

What Trent and his colleagues have done is expand on that basic premise, according to the study published in Proceedings of the National Academy of Sciences. Rather than just work with an inert piece of endotoxin, they’ve engineered E. coli bacteria to express the endotoxin in many configurations on the cell surface.

“These 61 E. coli strains each have a different profile on their surface,” says Brittany Needham, a doctoral student in Trent’s lab and the first author on the paper. “In every case the surface structure of the endotoxin is safe, but it will interact with the immune system in a range of ways. Suddenly we have a huge potential menu of adjuvants to test out with different kinds of vaccines.”

One form might work better with cholera vaccine, another with pertussis (whooping cough), and another with a future HIV vaccine. Trent, Needham, and their colleagues should be able to fine-tune the adjuvants with increasing precision as more E. coli strains are engineered and tested, and as their understanding of how they interact with the immune system deepens.

“I think we’re at the dawn of a new age of vaccine design,” Trent says. “For a long time vaccinology was really a trial-and-error field. It was a black box. We knew certain things worked. We knew certain vaccines had certain side effects. But we didn’t entirely know why. Now that’s changing.”

An additional advantage of their system is that the E. coli can be engineered to express key viral and bacterial antigens along with the endotoxin. A single cell could deliver both parts of the one-two punch, or even a one-two-three punch, if antigens from multiple diseases were expressed in a single E. coli.”It makes possible a vaccine that provides protection from multiple pathogens at the same time,” Trent says.

The researchers are working on a second round of designer E. coli. They have also filed a provisional patent on their system and are working with the university to find a corporate partner to pay for clinical trials.

“This is ready to go,” Trent says “I can’t predict whether it will actually make it to the market. But it’s very similar to the adjuvant that has already been approved, and my instinct is that if a company will undertake to do the trials, it will get approved. A company could call us tomorrow, we could send them a strain, and they could start working.”

Source: University of Texas at Austin

chat2 Comments

You are free to share this article under the Creative Commons Attribution-NoDerivs 3.0 Unported license.

2 Comments

  1. HH

    Here’s what Mr. Trent didn’t tell you about the new adjuvant:

    http://gaia-health.com/gaia-blog/2013-01-26/new-generation-of-vaccine-adjuvants-worst-ever/

  2. Don M

    While I, like many others, am excited to see humanity moving forward at exponential rates in areas of understanding and manipulation of the world around us, stories like this chill me to my core.

    To think that scientists would knowingly manipulate E. Coli with the intent to inject it into children, teens and adults in order to illicit an improved immune response is commendable, but it would seems to be wrought with potential for catastrophic results.

    What happens when they start to mutate through the batch before injection? What happens when they start to mutate in Vivo and transfer to another host?

    They are bacteria, it is in their nature to mutate and it’s not something that can inherently be controlled, especially once they are injected into the patient.

    The other side of this of course is the blind adherence by the industry and government that Vaccine’s can do no harm. Such a position would prevent an honest evaluation of the results of such genetic manipulations and adjuvant use once it becomes standard protocol used by vaccine manufacturers who have shown repeatedly that they can’t effectively control their manufacturing lines to prevent a wide array of contamination and catastrophes. Such problems would only be compounded by the shipping and storage of vaccines at clinics prior to their use that has often been found to vary from less than optimal to nonexistent introducing even more potential problems into the product.

    Controlling and preventing such things in a simple lab environment is easy, however once they leave the lab the conditions and results are shrouded behind multiple layers that seek to avoid accountability at all costs.

We respect your privacy.